Lata Mukundan

Amgen (United States) — United States

Medicine · Health Sciences

22h-index9.0kcitations41works20.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(10), Immune cells in cancer(9), Adipokines, Inflammation, and Metabolic Diseases(7), Protein Degradation and Inhibitors(6), Immune Cell Function and Interaction(5)

Publications41 total

1991P Overall survival (OS) with sotorasib plus carboplatin and pemetrexed in KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) from the global phase Ib CodeBreaK 101 study
Annals of Oncology·2025
Biomarkers of emergent resistance to sotorasib plus panitumumab in <i>KRAS</i> G12C-mutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreaK 300 study.
Journal of Clinical Oncology·2025· 1 cited
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer
Nature Medicine·2025· 19 citedOpen Access
Seven-day versus 14-day antibiotic course for culture-proven neonatal sepsis: a multicentre randomised non-inferiority trial in a low and middle-income country
Archives of Disease in Childhood Fetal & Neonatal·2025· 3 cited
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study
Leukemia & lymphoma/Leukemia and lymphoma·2024· 27 citedOpen Access
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial
Nature Medicine·2024· 73 citedOpen Access
Abstract 2308: Biomarkers of acquired resistance to sotorasib (soto) plus panitumumab (pani) in chemorefractory <i>KRAS</i> G12C-mutated metastatic colorectal cancer (mCRC)
Cancer Research·2023· 5 cited
Supplementary Figures S1 and S2: Association of MRD with survival outcomes in myeloma patients from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
2023Open Access
Supplementary Table S1: IMWG Criteria for MRD negativity from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
2023Open Access
Supplementary Table S1: IMWG Criteria for MRD negativity from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
2023Open Access
Supplementary Table S2: Clinical trials in myeloma using MRD assessments from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
2023Open Access
Data from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
2023Open Access
Supplementary Figures S1 and S2: Association of MRD with survival outcomes in myeloma patients from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
2023Open Access
Data from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
2023Open Access
Supplementary Table S2: Clinical trials in myeloma using MRD assessments from The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications
2023Open Access
Case Studies for Overcoming Challenges in Using Big Data in Cancer
Cancer Research·2023· 20 citedOpen Access
Challenges to Using Big Data in Cancer
Cancer Research·2023· 53 citedOpen Access
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration
Clinical Cancer Research·2021· 63 citedOpen Access
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia
JAMA Oncology·2017· 530 citedOpen Access
A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced Interpreters
Cytometry Part B Clinical Cytometry·2017· 40 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Ajay Chawla(14), Gary J. Kelloff(14), Caroline C. Sigman(14), Howard R. Higley(13), J. Milburn Jessup(12), Ilan R. Kirsch(12), Justin I. Odegaard(10), Gregory H. Reaman(10), Kenneth C. Anderson(10), Daniel Auclair(10), Hervé Avet‐Loiseau(10), Nicole Gormley(10), Shaji Kumar(10), Ola Landgren(10), Alessandra Di Bacco(10), Trevor J. Pugh(10), Nancy Valente(10), Elena Zamagni(10), Ann T. Farrell(9), Michèle Cavo(9)